Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
Invasive fungal infection is an increasing source of morbidity and mortality in patients with hematologic malignancies, particularly those with prolonged and severe neutropenia (absolute white blood cell count < 100/microL). Early diagnosis of invasive fungal infection is difficult, suggesting that antifungal prophylaxis could be the best approach for neutropenic patients undergoing intensive myelosuppressive chemotherapy. Consequently, antifungal prophylaxis has been extensively studied for more than 20 years. Nonabsorbable polyenes reduce superficial mycoses but are not effective in preventing or treating invasive fungal infections. Intravenous amphotericin B and the newer azoles were used in numerous clinical trials, but the value of antifungal prophylaxis in defined risk groups with cancer is still open to discussion. Recipients of allogeneic stem cell transplants and patients with a relapsed leukemia are high-risk patient populations. In addition, certain risk factors are well defined, for example, neutropenia more than 10 days, corticosteroid therapy, sustained immunosuppression, and graft-versus-host disease. In contrast to study efforts, evidence-based recommendations on the clinical use of antifungal prophylaxis according to risk groups are rare. The objective of this review of 50 studies accumulating more than 9000 patients is to assess evidence-based criteria with regard to the efficacy of antifungal prophylaxis in neutropenic cancer patients.
Cornely
Oliver A
OA
Klinik I für Innere Medizin, Klinikum der Universität Köln, Cologne, Germany.
Ullmann
Andrew J
AJ
Karthaus
Meinolf
M
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D004337:Drug Carriers; D019317:Evidence-Based Medicine; D006086:Graft vs Host Disease / Q000150:complications; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D008081:Liposomes; D009181:Mycoses / Q000453:epidemiology / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D012008:Recurrence; D012307:Risk Factors; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D014230:Triazoles; D000666:Amphotericin B